D3 Bio, a global biotech company that develops new cancer treatments, has raised $108 million in its Series B funding round.
The funding round was supported by well-known investors such as IDG Capital and SongQing Capital.
Existing investors — including WuXi AppTec’s Corporate Venture Fund, Temasek, HSG, MPCi, and Medicxi — also joined in. Their strong participation shows that both new and old investors trust D3 Bio’s innovative drug pipeline and global growth plans.
The money raised will mainly be used to fund global Phase III trials for D3 Bio’s main drug, elisrasib (D3S-001).
These important studies will test elisrasib alone and together with other treatments for KRAS G12C-mutant cancers. The trials will take place in major regions like the US, China, and the EU to support future global approvals.
The new funding will also help D3 Bio continue developing its full range of targeted therapies and cancer immunotherapy programs. These programs focus on new scientific approaches that could lead to breakthrough or best-in-class treatments.
Dr. George Chen, Founder, Chairman, and CEO of D3 Bio, stated, “The completion of our Series B financing demonstrates the strong confidence our investors place in our vision, scientific approach, business operations, and global development capabilities. This funding enables us to advance our lead program into late-stage clinical trials and further expand our pipeline of innovative therapies designed to benefit patients globally.”
Dr. Antoine Yver, Member of the Board of Directors and Scientific Committee of D3 Bio, stated, “This financing demonstrates that the swift and effective pursuit of the best- or first-in-class science is meaningful to society, and validates D3 Bio’s leading innovation, scientific vision and development strategy. It also highlights the unique potential of elisrasib for individuals affected by KRAS G12C-mutant cancers.”
D3 Bio is a global biotech company that works on discovering, developing, and getting approval for new medicines in cancer and immune-related diseases. The company uses its own scientific tools and biomarker strategies to create meaningful treatments for patients who need better options.
Its cancer programs focus on key genetic mutations and important immune pathways, with the goal of creating breakthrough or best-in-class drugs. D3 Bio also fully owns the worldwide rights to all of its programs.
Read More- Virtusa Strengthens Chip Design Capabilities with Acquisition of SmartSoC Solutions
